NFKB1 and acute respiratory distress syndrome: Since EEAO was reported to decrease lung inflammation and ALI by suppressing NF-κB, a pro-inflammatory transcription factor, and by activating Nrf2, an anti-inflammatory transcription factor, we first examined whether alismol inhibits NF-κB activity for suppressing lung inflammation and ALI.